在心脏移植患者中,添加阿利罗库马布与他类药物可使LDL胆固醇降低50%以上,但不能显著降低斑块的进展. Adding alirocumab to statins cut LDL cholesterol by over 50% in heart transplant patients, but didn’t significantly reduce plaque progression.

在美国心脏协会2025年科学会议上进行的一项临床试验发现,一年后,将PCSK9抗抑制剂Alirocumab添加到 Statin疗法中,心脏病移植病人的LDL胆固醇减少了50%以上,从72.7毫克/dL降至31.5毫克/dL。 A clinical trial presented at the American Heart Association's 2025 Scientific Sessions found that adding the PCSK9 inhibitor alirocumab to statin therapy reduced LDL cholesterol by over 50% in heart transplant patients, lowering levels from 72.7 mg/dL to 31.5 mg/dL after one year. CAVIAR研究涉及114名最近移植的成年人,研究表明,这种结合对于胆固醇控制是安全和有效的,但并未显著减少冠动脉板的进化。 The CAVIAR study, involving 114 recently transplanted adults, showed the combination was safe and effective for cholesterol control but did not significantly reduce coronary artery plaque progression. 研究人员指出,低基线标志和LDL水平可能限制了研究发现差异的能力。 Researchers noted low baseline plaque and LDL levels may have limited the study’s ability to detect differences. 虽然积极的胆固醇管理得到支持,但长期结果和更广泛的效益仍然不确定,突出表明需要进一步的研究。 While aggressive cholesterol management is supported, long-term outcomes and broader benefits remain uncertain, highlighting the need for further research.